secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2021-11-18T23:59:59+00:00
Accession:  0000950170-21-004749
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead exercises options on three Arcus programs for $725M; co-development and profit sharing
--------------------------------------------------------------------------------

- Gilead paid $725M in option fees to exercise rights to three Arcus programs: anti-TIGIT, adenosine antagonist, and CD73.
- Companies will co-develop and equally share US profits/losses; Gilead gets ex-US rights with mid-teens to low-twenties royalties.
- Two new research targets added; Gilead can option each for $60M after IND-enabling activities; royalties high-single to low-double digits.
- The existing $100M 2022 Continuation Payment will be eliminated if all three programs close; reduced if fewer close.
- Transaction subject to HSR antitrust review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000095017021004749/0000950170-21-004749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000095017021004749/rcus-20211117.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-004749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer